Is the Wegovy pill the same as injectable Wegovy?

The Wegovy pill contains the same active ingredient (semaglutide) as Wegovy injections, but it is formulated for oral delivery with different dosing. It is absorbed differently in the body, so the dose strengths are not directly interchangeable with the injection.

When was the Wegovy pill approved?

The FDA approved oral semaglutide for chronic weight management in December 2025. It became the fastest drug launch in pharmaceutical history by prescription volume in its first weeks on the market.

Do I need to fast before taking the Wegovy pill?

Yes. Oral semaglutide must be taken on an empty stomach with no more than 4 ounces of plain water. You should not eat, drink, or take other oral medications for at least 30 minutes after taking it. This fasting requirement is a key difference from the injection.

Is the Wegovy pill covered by insurance?

Coverage is expanding but still inconsistent. Some insurance plans cover it similarly to injectable Wegovy, while others have not yet added it to their formularies. Manufacturer savings cards can reduce the cost significantly for commercially insured patients.

How much weight can I lose on the Wegovy pill?

Clinical data shows weight loss in the range of 12-15% of body weight over 68 weeks, which is comparable to injectable Wegovy. Results vary by individual based on dose, adherence, diet, and other factors.

Guide

The Wegovy Pill: What You Need to Know (2026)

The Wegovy pill (oral semaglutide) became the fastest drug launch in history after FDA approval in December 2025. Here's how it compares to the injection, who should take it, and what it costs.

Updated April 2026Editorially ReviewedEditorial Independence

What is the Wegovy pill?

The Wegovy pill is the oral formulation of semaglutide, the same active ingredient in the Wegovy injection and Ozempic. Novo Nordisk received FDA approval for oral semaglutide as a chronic weight management treatment in December 2025, and demand was immediate. By most industry measures, it became the fastest drug launch in pharmaceutical history in terms of initial prescription volume.

The pill works the same way as injectable semaglutide: it activates GLP-1 receptors to reduce appetite, slow gastric emptying, and increase feelings of fullness. The difference is entirely in the delivery method. Instead of a weekly subcutaneous injection, patients take a tablet once daily. For the millions of people who have avoided GLP-1 therapy specifically because of needle phobia, this is a big deal.

ClearlyMeds is an independent editorial team. Revenue never influences our rankings, and every guide is written to help readers understand tradeoffs in plain English rather than push a single provider.

The pill is available in three dose strengths: 7mg, 14mg, and 25mg. These doses are lower on a milligram basis than the injectable versions because oral semaglutide has lower bioavailability (less of the drug makes it into your bloodstream when swallowed compared to injection). Despite the lower milligram numbers, the clinical effect is similar.

How the pill compares to the Wegovy injection

Efficacy is the first question most patients ask. The data shows that oral semaglutide produces weight loss in the 12-15% range over 68 weeks, which is broadly comparable to injectable Wegovy. The injection may have a slight edge at the highest doses, but the difference is small enough that most patients would not notice a meaningful gap in real-world results.

The bigger differences are practical. The pill requires a strict fasting protocol: take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking any other oral medications. Many patients find this routine manageable, but it is more restrictive than the injection, which has no food or beverage requirements.

Side effects are similar between the two formats. Nausea, vomiting, diarrhea, and constipation are the most common issues with both. Some clinicians report that the pill may cause slightly more gastrointestinal irritation in the first few weeks because the drug passes through the stomach directly, but this is anecdotal and varies by individual.

Same active ingredient, different delivery method
Similar weight loss results (12-15% over 68 weeks)
Pill requires 30-minute fasting before and after
Side effect profile is comparable
Daily pill vs weekly injection

Cost and insurance coverage

The list price for oral semaglutide is expected to be in the same range as injectable Wegovy, which has a list price around $1,349 per month. However, very few patients pay list price. Novo Nordisk offers a savings card that can bring the cost down to $25 per month for commercially insured patients who are approved. Uninsured patients or those denied by insurance face much higher costs.

Insurance coverage is still catching up. Because the pill was approved in December 2025, many formularies have not yet added it. Injectible Wegovy has much broader coverage since it has been available since 2021. Patients considering the pill should check with their insurer specifically about oral semaglutide coverage, not just Wegovy in general, because some plans cover the injection but not the oral formulation.

Telehealth providers like [Ro](/reviews/ro), [Hims](/reviews/hims), and [Found](/reviews/found) can help patients navigate insurance approval and may offer cash-pay options if coverage is denied. [Noom](/reviews/noom) pairs medication access with behavioral coaching, which some patients find helpful for long-term success. For a full comparison of oral GLP-1 options, see our [best oral GLP-1 guide](/best-for/best-oral-glp1).

Who should consider the Wegovy pill

The Wegovy pill is best suited for adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 or higher) who also have a weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. Within that population, the pill is particularly appealing for people who have delayed or avoided GLP-1 treatment because of injection anxiety.

The pill may also be a good fit for patients who prefer the psychological routine of a daily medication over a weekly injection. Some people find it easier to remember a pill with their morning routine than to schedule a specific day each week for an injection. Others may prefer the opposite, so there is no universally better format.

Patients who struggle with the fasting requirement or who have unpredictable schedules may find the injection more practical. The pill demands consistency in timing and fasting that the injection does not. Patients with gastrointestinal conditions that might be aggravated by oral medication should discuss the options with their clinician.

This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.

Wegovy pill vs orforglipron

With two oral GLP-1 options now available, patients will naturally want to compare them. The Wegovy pill (oral semaglutide) is from Novo Nordisk and requires a fasting protocol. Orforglipron is from Eli Lilly, does not require fasting, and is a small molecule with potentially lower manufacturing costs. Both produce similar weight loss results in the 12-15% range.

For a detailed look at orforglipron specifically, see our [complete orforglipron guide](/guides/orforglipron-everything-to-know). For a broader comparison of all GLP-1 medications including injectables, our [Wegovy vs Zepbound comparison](/compare/wegovy-vs-zepbound) covers the full landscape.

The right choice between these oral options will depend on insurance coverage (which may favor one over the other), clinician preference, side effect tolerance, and whether the fasting requirement of the Wegovy pill is a dealbreaker. Both represent a major step forward in making GLP-1 therapy accessible to more people. Visit our [weight loss provider comparison](/weight-loss) to see which platforms offer each option.